Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume - Should You Buy?

Key Points

• Bavarian Nordic experienced a decline in trading volume, with approximately 6,547 shares traded, down 12% from the previous day's volume.
• The stock is currently trading at $11.96, which is lower than its previous close of $12.13.
• The company reported $0.13 EPS for the last quarter, with revenue totaling $189.89 million and a net margin of 21.11%.
• Bavarian Nordic has a market capitalization of $2.86 billion and analysts predict an EPS of 0.67 for the current year.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) shares saw unusually-strong trading volume on Friday . Approximately 6,547 shares changed hands during trading, a decline of 12% from the previous session's volume of 7,456 shares.The stock last traded at $11.96 and had previously closed at $12.13.

Bavarian Nordic Price Performance

The firm has a market capitalization of $2.88 billion, a P/E ratio of 15.23 and a beta of 1.36. The stock has a fifty day simple moving average of $9.24 and a two-hundred day simple moving average of $8.43.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported $0.13 earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 11.89% and a net margin of 21.11%. The business had revenue of $189.89 million during the quarter. As a group, sell-side analysts expect that Bavarian Nordic will post 0.67 EPS for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.